肿瘤细胞治疗研究
英文原题：Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma.
肝细胞癌（HCC）是全球癌症相关死亡的第四大常见原因。
肝细胞癌（HCC）是全球癌症相关死亡的第四大常见原因。患者确诊时往往已处于晚期，根治性手术后复发也较常见。近年来，免疫检查点抑制剂（ICI）改变了晚期HCC的治疗格局，尤其是阿替利珠单抗联合贝伐珠单抗成为一线治疗新标准。近期，度伐利尤单抗联合曲美木单抗双重阻断免疫检查点也成为晚期HCC的有效一线方案。目前研究重点主要是开发以ICI为基础的联合疗法。本文综述晚期HCC免疫联合治疗的理论依据和正在开展的临床试验，并讨论CAR-T 细胞及抗癌疫苗等新型免疫治疗策略。
Hepatocellular carcinoma (HCC) is the fourth most frequent cause of cancer-related death worldwide. HCC frequently presents as advanced disease at diagnosis, and disease relapse following radical surgery is frequent. In recent years, immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced HCC, particularly with the introduction of atezolizumab/bevacizumab as the new standard of care for first-line treatment. Recently, dual immune checkpoint blockade with durvalumab plus tremelimumab has also emerged as an effective first-line treatment for advanced HCC and most of the research is currently focused on developing combination treatments based mainly on ICIs. In this review, we will discuss the rationale and ongoing clinical trials of immune-based combination therapies for the treatment of advanced HCC, also focusing on new immunotherapy strategies such as chimeric antigen receptor T cells (CAR-T) and anti-cancer vaccines.
MEMBER ACCOUNT
登录成功会直接打开下一页。
